Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00244127
Status:
UNKNOWN
Last Update Posted:
2005-10-28
First Post:
2005-10-24
Brief Title:
Open Label Single Arm Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL
Sponsor:
Zeneus Pharma
Organization:
Zeneus Pharma
Study Overview
Official Title:
Cyclophosphamide Oncovin Myocet Prednisone and Rituximab R-COMP in the Treatment of Elderly Patients With Aggressive NHL
Status:
UNKNOWN
Status Verified Date:
2005-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL Myocet non-pegylated liposomal doxorubicin replaces conventional doxorubicin in the R-CHOP regimen
Detailed Description:
To evaluate the duration of remission disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| The MYOCAN Study | None | None | None |